Levormeloxifene
Names | |
---|---|
IUPAC name
1-(2-{4-[(3R,4R)-7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydro-2H-chromen-4-yl]phenoxy}ethyl)pyrrolidine | |
Identifiers | |
31477-60-8 | |
3D model (Jmol) | Interactive image |
ChEMBL | ChEMBL301327 |
ChemSpider | 32935 |
PubChem | 35805 |
UNII | 9512UKZ352 |
| |
| |
Properties | |
C30H35NO3 | |
Molar mass | 457.604 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
verify (what is ?) | |
Infobox references | |
Levormeloxifene is an experimental selective estrogen receptor modulator that was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss. The development was stopped because of a high incidence of gynaecologic adverse events during clinical trials.[1] It is the enantiomer of ormeloxifene.
References
- ↑ Ravn P; Nielsen TF; Christiansen C. (2006). "What can be learned from the levormeloxifene experience?". Acta Obstet Gynecol Scand. 85 (2): 135–42. doi:10.1080/00016340500345691. PMID 16532904.
This article is issued from Wikipedia - version of the 11/7/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.